The maker of EzriCare Artificial Tears said it was recalling the eye drops after U.S. health authorities linked the product to a drug-resistant bacteria strain.

The godfather of vaccines discussing the future of vaccinology — dr. stanley plotkin, MD.

Dr. Stanley Plotkin, MD (https://en.wikipedia.org/wiki/Stanley_Plotkin), is an American physician, scientist, and scholar, who in the 1960s, while working at Wistar Institute in Philadelphia, played a pivotal role in discovery of a vaccine against rubella virus (which is now used worldwide as a key component of the MMR vaccine), and has worked extensively on the development and application of a wide range of other vaccines including those for polio, rabies, varicella, rotavirus and cytomegalovirus (https://www.epiv.eu/).

Dr. Plotkin graduated from New York University in 1952 and obtained a medical degree at Downstate Medical Center in Brooklyn. He was a resident in pediatrics at the Children’s Hospital of Philadelphia and at the Hospital for Sick Children in London.

In 1957, Dr. Plotkin served in the Epidemic Intelligence Service of the Centers for Disease Control (CDC) of the U.S. Public Health Service for three years and then served as a member of Wistar’s active research faculty from 1960 to 1991.

Today, in addition to his emeritus appointment at Wistar, Dr. Plotkin is emeritus professor of Pediatrics at the University of Pennsylvania (https://www.med.upenn.edu/apps/faculty/index.php/g275/p1554), and works as a consultant advising vaccine manufacturers, biotechnology firms, non-profits and governments.

There should be some vaccine against common cold because globally millions of people suffer s due to this disease.

Vaccines are an effective public health strategy, but so far, science has not been able to develop one for the common cold.

In a recent study published in Scientific Reports, researchers identified serological Hepatitis C virus (HCV) signatures and human immunodeficiency virus (HIV) signatures through the secondary utilization of ribonucleic acid sequencing (RNA-seq) analysis data among previous and existing smokers with or without COPD (chronic obstructive pulmonary disease).

Viral detection by RNA sequencing analysis has increased the knowledge base of viruses causing human infections. Identifying undiagnosed viral infections by using existing nucleic acid sequencing data could facilitate epidemiological survey-based analysis and aid in the development of diagnostic and therapeutic options for improved population health.

If you enjoy some good toilet technology, then I think “urine” for a treat. Starling Medical is poised to launch its at-home urine diagnostic patient-monitoring platform, dubbed “StarStream,” that doesn’t rely on the traditional catching containers or dipsticks.

Now, if you’re thinking this technology sounds familiar, you would be correct: My colleague Haje Jan Kamps wrote about Withings’ U-Scan, a urinalysis device, earlier this month when the health-focused consumer tech company debuted it at CES. U-Scan also sits in the toilet for at-home monitoring.

However, Alex Arevalos, Starling’s co-founder and CEO, told TechCrunch that this is an underserved market — the global urinalysis market is forecasted to be valued at $4.9 billion by 2026, meaning there is plenty of room for Withings and a scrappy startup.